
ImmunoPrecise Unveils AI-Powered Breakthrough in Universal Dengue Vaccine Development
ImmunoPrecise Achieves AI-Driven Breakthrough in Universal Dengue Vaccine Development ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), a leader in AI-driven biotherapeutics, has announced a groundbreaking discovery that could pave the way for a universal dengue vaccine. Using its proprietary LENSai™ platform…












